Lille

• The TARGET BP I Ended recruitment
  2024-512525-83-00 5 2020-01-07 Hypertension
• Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou … Ended recruitment
  2023-509049-11-00 5 2020-01-01 FIGO stage III ovarian cancer who are eligible for primary cytoreducti
• A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and … Ended recruitment
  2024-514829-36-00 5 2019-12-02 High-risk biochemically-relapsed prostate adenocarcinoma following rad
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, … Ended recruitment
  2024-516847-23-00 4 2019-08-27 ER-positive and HER2-negative metastatic or locally advanced breast ca
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l … Ended recruitment
  2022-502616-37-00 9 2019-07-30 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
• Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi … Ended recruitment
  2024-515946-17-00 5 2019-07-22 Non Small Cell Lung Cancer
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk … Ended recruitment
  2023-505223-31-00 4 2019-06-14 Localized ER+ breast cancer
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended recruitment
  2024-512165-13-00 4 2019-05-13 Localised unresectable adenocarcinoma or squamous cell carcinoma of th
• An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Ended recruitment
  2024-515690-10-00 9 2019-05-10 Diffuse large B-cell lymphoma
• Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different … Ended recruitment
  2024-514706-31-01 5 2019-05-02 Epithelial ovarian cancer, Fallopian tube ovarian cancer, Peritoneal o
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter … Ended recruitment
  2022-501485-22-00 5 2018-12-18 Myelodysplastic syndrome (MDS)
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck
• A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy Ended recruitment
  2024-510713-15-00 4 2018-07-30 Localised and operable soft tissue sarcomas
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended recruitment
  2024-512470-10-00 11 2018-02-02 End-stage Renal disease
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea … Ended recruitment
  2023-506399-28-00 5 2017-11-08 Crohn's Disease
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended recruitment
  2023-503438-40-00 7 2017-10-05 Relapsed/Refractory Multiple Myeloma
• Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended recruitment
  2024-513964-24-00 5 2017-09-14 Squamous cell carcinoma, previously untreated Stage III, stage IVa (op
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-506390-35-00 1 2017-04-19 Patients with Advanced Solid Tumors
• A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Ended recruitment
  2023-505625-14-00 7 2017-01-31 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
• Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended recruitment
  2024-513972-16-00 5 2017-01-30 - Resected tumors of sinuses or salivary glands - Non-operable tumors

Showing 529–552 of 703 trials